Ranolazine, Ethnicity and the Metabolic Syndrome

PHASE4UnknownINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

July 31, 2013

Study Completion Date

November 30, 2013

Conditions
Coronary Artery DiseaseAnginaMetabolic Syndrome
Interventions
DRUG

Ranolazine

Patients in the ranolazine arm would start with 500 mg po BID of ranolazine and be force titrated to 1gm po BID after 2 weeks. Down-titration would only be allowed for side effects. This would be on top of all standard medical therapy.

Trial Locations (2)

30041

Atlanta Heart Specialist, LLC, Cumming

30084

Atlanta Heart Specialists, LLC, Tucker

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Gilead Sciences

INDUSTRY

lead

Atlanta Heart Specialists, LLC

OTHER